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1 |  INTRODUCTION
We demonstrate the effectiveness of readministering cetux-
imab as a salvage chemotherapeutic agent after nivolumab 
administration to a patient with a recurrence of cervical 
lymph node metastasis after tongue cancer surgery. We can 
infer that the immunostimulatory effect of nivolumab and re-
activation of cetuximab enhance the antitumor effect of the 
therapy.
In March 2017, nivolumab, an immune checkpoint inhib-
itor, was approved for treating squamous cell carcinoma of 
the head and neck with recurrence or metastasis in Japan. 
Nivolumab differs from conventional chemotherapeutic 
drugs; it is known to elicit a reaction and has been reported 
to be highly effective for lung cancer when administered after 
immunotherapy. However, few reports of its use for head and 
neck cancer treatment are available. Here, we present the case 
of a patient who had recurrent cervical lymph node metasta-
sis due to tongue cancer. The administration of cetuximab and 
nivolumab led to increased metastasis; however, the readmin-
istration of cetuximab resulted in a remarkable response.
2 |  CASE REPORT
A 55- year- old patient (height, 160 cm; weight, 52 kg; with 
good nutritional status) presented to our hospital with an ulcer 
on the right tongue margin in June 2015. The patient had been 
previously diagnosed with endometrial atypical growth by 
the obstetrics and gynecology department of a nearby hospi-
tal in December 2012. The patient neither consumed alcohol 
nor smoked and had no family history of cancer. An extraoral 
examination revealed no abnormal findings in the cervical 
lymph nodes; however, an intraoral examination using mag-
netic resonance imaging (MRI) showed an ulcerative lesion 
with a diameter of approximately 22 mm on the right tongue 
margin (Figure 1A). Moreover, infiltrative lesions showing 
a contrast effect with gadolinium were observed in the right 
tongue area (Figure  1B,C). Positron emission tomography 
(PET) showed a high accumulation of fluorodeoxyglucose in 
the right tongue margin, but not in other organs (Figure 1D). 
Based on these findings and the pathological evaluation of 
an intraoral biopsy specimen, we diagnosed the patient with 
stage II (T2N0M0) squamous cell carcinoma of the tongue.1
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We can infer that the immunostimulatory effect of nivolumab and reactivation of 
cetuximab enhance the antitumor effect of the therapy.
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In July 2015, the patient underwent partial right tongue 
resection under general anesthesia. Postoperative adjuvant 
therapy was not administered because the surgical margin 
was negative. Although recurrence was not observed locally 
or in the neck, swelling of the right cervical region was ob-
served in December 2015 and the patient was followed up 
F I G U R E  1  (A) Photograph taken 
during the patient's initial visit, showing an 
ulcerative lesion measuring approximately 
22 mm in diameter on the right tongue 
margin. (B) Magnetic resonance image 
showing frontal disconnection. (C) 
Magnetic resonance image in the horizontal 
view. An invasive lesion showing a contrast 
effect with gadolinium was observed on 
the right tongue margin. (D) Positron 
emission tomography image showing a high 
accumulation of fluorodeoxyglucose in the 
right tongue margin
F I G U R E  2  (A) Magnetic resonance image taken 7 months after tongue cancer surgery. The right superior- internal jugular vein lymph node 
had become swollen with a minor axis of approximately 12 mm, and the T2- weighted image shows a region with moderate signal intensity that 
included a part of the low- signal region. (B) Computed tomography image taken 3 months after right neck dissection. The right submandibular 
lymph node had become swollen with a minor axis of approximately 15 mm, and the boundary with the surrounding area was unclear. (C) 
Computed tomography image taken after chemoradiotherapy. No change in the size of the right submandibular lymph node was observed, and the 
boundary with the surrounding area was unclear
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with monthly MRI thereafter. MRI performed in February 
2016  showed that the right superior- internal jugular vein 
lymph node had a minor axis of approximately 12 mm. The 
patient was then diagnosed with late cervical lymph node 
metastasis of tongue cancer because MRI showed a region 
with moderate signal intensity that included a part of the 
low- signal region (Figure 2A). In the same month, the patient 
underwent right total neck dissection under general anesthe-
sia. Postoperative adjuvant therapy was not administered at 
this time because histopathological diagnosis did not detect 
extracapsular invasion in the right superior- internal jugular 
vein lymph node.
The patient was followed up, and swelling was observed 
in the lower part of the patient's right jaw in May 2016. 
Computed tomography (CT) showed that the right subman-
dibular lymph node had become swollen with a minor axis 
of approximately 15  mm and that the boundary with the 
surrounding area was unclear (Figure 2B). Recurrence was 
confirmed after the patient was diagnosed with late cervi-
cal lymph node metastasis of tongue cancer, and chemora-
diotherapy (cisplatin [cis- diamminedichloroplatinum II] total 
dose, 300 mg/m2; radiotherapy total dose, 66 Gy) was initi-
ated from the same month onward, which resulted in a stable 
disease (Figure 2C).
F I G U R E  3  (A) Computed tomography image taken after three courses of cetuximab combination chemotherapy. The right submandibular 
recurrent lymph node had disappeared. (B) Computed tomography image taken 3 months after the maintenance therapy of cetuximab alone was 
initiated. Swelling of the right submandibular lymph node was observed. (C) Computed tomography image taken after six doses of nivolumab. 
Shrinkage of the right submandibular lymph node was observed. (D) Computed tomography image taken after 14 doses of nivolumab. Significant 
enlargement of the right submandibular lymph node was observed. (E) Computed tomography image taken after three courses of chemotherapy 
with cetuximab. Significant reduction of the right submandibular recurrent lymph node was observed. (F) Computed tomography image taken after 
52 doses of cetuximab alone. The right submandibular lymph node had disappeared
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Chemotherapy with cetuximab was initiated in September 
2016. Cetuximab was initially administered at a dose of 
400 mg/m2 and subsequently at a dose of 250 mg/m2 once 
weekly. Moreover, cisplatin was administered at a dose of 
80  mg/m2 on Day 1, and fluorouracil was administered at 
a dose of 800 mg/m2 on Days 1– 4. CT was performed in 
December 2016, at the end of the three courses of cetuximab 
combination chemotherapy. The recurrent lymph node had 
disappeared and a complete response (CR) was therefore 
recorded (Figure  3A). Paronychia of the limbs, which was 
considered a skin reaction triggered by cetuximab, was ob-
served; however, it only caused mild pain and improved with 
the application of a moisturizer. Cetuximab alone was main-
tained from the same month onward at a dose of 250 mg/m2 
once weekly.
Another CT was performed in March 2017, 3 months after 
the maintenance therapy of cetuximab alone was initiated, 
which revealed that the right submandibular lymph node was 
swollen. Therefore, the treatment response was classified as 
progressive (Figure 3B). Nivolumab therapy was then initi-
ated at a dose of 3 mg/kg once every 2 weeks. No immune- 
related adverse events due to nivolumab were observed. CT 
was performed again in July 2017, following the administra-
tion of six doses of nivolumab, which revealed shrinkage of 
the right submandibular lymph node (Figure 3C). The treat-
ment response was categorized as partial, and nivolumab ad-
ministration was continued.
In October 2017, however, after 14 courses of nivolumab, 
swelling of the right submandibular gland was observed; CT 
revealed a marked increase in the right submandibular lymph 
node size (Figure 3D). Thus, the patient was considered to 
have a progressive disease, and cetuximab combination che-
motherapy was recontinued from the same month onward. 
The dose and dosing interval were the same as previously 
implemented. The next CT was performed in February 2018, 
following three courses with the readministration of cetux-
imab combination chemotherapy, which showed that the 
right submandibular recurrent lymph node was markedly re-
duced in size (Figure 3E). From the same month onward, the 
patient received a maintenance therapy of cetuximab alone. 
The final CT was performed in March 2019, after 52 doses of 
cetuximab. The submandibular lymph node had disappeared, 
and CR was achieved (Figure 3F). Cetuximab alone was still 
being administered as the maintenance therapy 20  months 
later. PET did not detect any recurrence or metastasis there-
after, and the course has been uneventful (Figure 4A,B).
3 |  DISCUSSION
With recent advances in drug therapies, such as molecular- 
targeted therapies and immune checkpoint inhibitors, the role 
of drug therapy in the treatment of head and neck cancer is 
rapidly expanding and its scope is becoming more complex.2 
In Japan, the anti- epidermal growth factor receptor anti-
body cetuximab was approved as a molecular- targeted drug 
for head and neck cancer in December 2012. Moreover, a 
2017 subanalysis of the CheckMate 141 trial found that the 
anti- programmed death 1 (PD- 1) antibody nivolumab had fa-
vorable effects in the treatment of recurrent and metastatic 
squamous cell carcinoma of the head and neck.3 Nivolumab 
is now being used as one of the standard treatments for head 
and neck cancer.3
Nivolumab has been shown to have responses and ther-
apeutic effects that are distinct from those of conventional 
anticancer and molecular- targeted drugs. Nivolumab treat-
ment has been reported to have long- lasting effects in suc-
cessful cases and suppress the exacerbation of tumors for 
F I G U R E  4  (A, B) Positron emission 
tomography images taken 20 months 
after complete response was achieved. No 
recurrence or metastasis was observed
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long periods in unchanged ones.4 Studies have suggested that 
salvage chemotherapy after the administration of previously 
approved immune checkpoint inhibitors is highly effective 
for treating non– small- cell lung cancer.5– 7
In the present study, recurrent lymph nodes disappeared 
after chemotherapy with cetuximab, but increased after the 
treatment was switched to cetuximab alone. Nivolumab 
was subsequently administered; however, because recurrent 
lymph nodes continued to increase, chemotherapy with cetux-
imab was initiated again. The patient subsequently showed a 
marked reduction in recurrent lymph nodes and continues to 
be in CR at present. These outcomes may be related to the 
reactivation of cetuximab and the immunostimulatory effect 
of nivolumab.
Regarding the reactivation of cetuximab, Santini et al.8 
found tumor growth after cetuximab was administered and 
readministered as an adjuvant therapy in 21 of 39 patients 
with colorectal cancer, 53.8% of whom reported a response. 
Moreover, regarding the mechanism by which the readmin-
istration of cetuximab is effective, Aparicio and Caldas9 
reported that there was a heterogeneous presence of cells 
that were sensitive to cetuximab and low- signal cells were 
present in the tumor. They found that the administration 
of cetuximab (1) initially led to a reduction in the number 
of sensitive cells, an increase in the number of insensitive 
cells, and tumor growth, but (2) subsequently resulted in 
an increase in the number of sensitive cells. These find-
ings suggest that the readministration of cetuximab shrinks 
tumors.
Regarding its immunostimulatory effect, nivolumab is a 
human immunoglobulin G4 anti- PD- 1 antibody.10 PD- 1, a re-
ceptor from the CD28 family,10 is expressed in immune cells, 
such as differentiated effector T cells and B cells, after acti-
vation. The binding of antigen- presenting cells to PD- L1 and 
PD- L2 ligands on lymphocytes, PD- L1 expressed on tumor 
cells, and PD- 1 expressed on T cells, which transmits a nega-
tive signal to T cells, suppresses their activation.10
Nivolumab restores anticancer immune response by 
inhibiting the binding of PD- 1 to PD- L1 and PD- L2 and 
subsequently diminishing inhibitory signals to T cells.10 
In addition, research has considered that conventional che-
motherapy suppresses cancer cell growth and cytotoxicity.4 
However, in recent years, it has become clear that immune 
cells represented by T cells are involved in long- term clin-
ical effects.4 Chemotherapeutic agents have been shown to 
act directly on immunocompetent and immunosuppressive 
cells as well as cancer cells, thereby affecting their antitumor 
effects.4
Cisplatin has been reported to increase the expression 
of tumor- specific antigens and promote the induction of 
antigen- associated cytotoxic T cells.11 In addition, paclitaxel 
is known to improve not only antigenicity by enhancing the 
expression of major histocompatibility complex class I mol-
ecules in cancer cells but also the ability of dendritic cells to 
present antigens to T cells by acting directly on the dendritic 
cells.12 Furthermore, fluorouracil has been shown to selec-
tively induce apoptosis in myeloid- derived suppressor cells 
and increase their antitumor effect.13
Change in the cancer immune microenvironment due to 
the administration of nivolumab influences the effects of suc-
ceeding chemotherapeutic agents used on immunocompetent 
and immunosuppressive cells, with the said influence being 
enhanced by its interaction with the original cell- killing ef-
fect. Limited data on the successful cases of rescue chemo-
therapy after the administration of such immune checkpoint 
inhibitors in oral cancer highlight the need for more cases to 
be reported.
4 |  CONCLUSION
Our case demonstrated the effectiveness of readministering 
cetuximab as a salvage chemotherapeutic agent after admin-
istering nivolumab in a patient diagnosed with progressive 
disease for the recurrence of cervical lymph node metasta-
sis after tongue cancer surgery. Our findings suggest that the 
immunostimulatory effect of nivolumab and reactivation of 
cetuximab enhance the antitumor effect of the therapy, which 
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